NEW ISSUE
Ischaemia with non-obstructive coronary arteries, OCT vs IVUS guidance in PCI; the ILUMIEN III and ILUMIEN IV trials…
January 20, 2021
Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France
An 87-year-old female was admitted for symptomatic failure of a 23 mm Carpentier-Edwards PERIMOUNT aortic bioprosthesis (Edwards Lifesciences, Irvine, CA, USA) implanted 17 years previously. Both severe central regurgitation and severe stenosis (mean gradient 60 mmHg) were identified. Due to a significant perioperative risk of redo surgery (EuroSCORE 46.5%, STS 7.3%), the Heart Team decided on transfemoral valve-in-valve (ViV) implantation. A 23 mm Edwards SAPIEN 3 (S3) device (Edwards Lifesciences) was chosen, based on a measured inner diameter of 20.5 mm by multislice computed tomography (MSCT) and of 21 mm as reported by the manufacturer. The ViV procedure was performed under conscious sedation and fluoroscopy guidance. The ...
Sign in to read and download the full article
Forgot your password?No account yet? Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Interventions for valvular diseaseTAVITools, devices and techniques
Read next article
Tools and Techniques – Statistical. Estimating cumulative incidences in the presence of right-censoring and competing risks: an introduction with illustrations from the COACH study